Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.

EBioMedicine - 1 Dec 2019

Song Bic-Na, Kim Seon-Kyu, Mun Jeong-Yeon, Choi Young-Deuk, Leem Sun-Hee, Chu In-Sun

Abstract excerpt

BACKGROUND: Although various molecular subtypes of bladder cancer (BC) have been investigated, most of these studies have focused on muscle-invasive BC (MIBC). A few studies have investigated non-muscle-invasive BC (NMIBC) or NMIBC and MIBC together, but none has classified progressive NMIBC or immune checkpoint inhibitor (ICI)-based therapeutic responses in early-stage BC patients. METHODS: A total of 1,934...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cluster Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Genetic

Share to Disease Susceptibility

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Unsupervised Machine Learning

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31735557
DOI: 10.1016/j.ebiom.2019.10.058
PMCID: PMC6921227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.PMID 31735557Read ↗

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)Semantic proximity Read ↗

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.Semantic proximity Read ↗

Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapiesSemantic proximity Read ↗

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancerSemantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

Molecular profile of bladder cancer progression to clinically aggressive subtypesSemantic proximity Read ↗

Update on bladder cancer molecular subtypesSemantic proximity Read ↗

Molecular subtyping of invasive bladder cancer: time to divide and rule?Semantic proximity Read ↗

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.